UTHR FY 2024 Earnings Report — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

United Therapeutics CorporationUTHR

FY 2024 Earnings

Reported February 26, 2025

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2024	Prior Q	FY 2023	QoQ Change	YoY Change
Revenue	$2.9B	—	$2.3B	—	23.6%
Op. Income	$1.4B	—	$1.2B	—	16.2%
Gross Margin	89.2%	—	88.9%	—	0.3pp
Net Margin	41.5%	—	42.3%	—	-0.8pp
EPS (Diluted)	$24.64	—	$19.81	—	24.4%
Free Cash Flow	$1.1B	—	$748M	—	44.5%

Revenue Flow

Item	Amount
REVENUE	$2.9B
Cost of Revenue	$310M
GROSS PROFIT	$2.6B
R&D Expenses	$481M
Selling & Marketing	$96M
General & Administrative	$542M
SG&A Expenses	$639M
Other Expenses	$71M
Operating Expenses	$1.2B
Cost & Expenses	$1.5B
OPERATING INCOME	$1.4B
Interest Income	$199M
Interest Expense	$43M
Other Income/Expenses	$162M
INCOME BEFORE TAX	$1.5B
Income Tax Expense	$344M
Net Income from Continuing Ops	$1.2B
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$1.2B
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$1.2B
D&A	$73M
EBIT	$1.6B
EBITDA	$1.7B
EPS	$26
EPS Diluted	$25

Income Statement

Item	Amount
REVENUE	$2.9B
Cost of Revenue	$310M
GROSS PROFIT	$2.6B
R&D Expenses	$481M
Selling & Marketing	$96M
General & Administrative	$542M
SG&A Expenses	$639M
Other Expenses	$71M
Operating Expenses	$1.2B
Cost & Expenses	$1.5B
OPERATING INCOME	$1.4B
Interest Income	$199M
Interest Expense	$43M
Other Income/Expenses	$162M
INCOME BEFORE TAX	$1.5B
Income Tax Expense	$344M
Net Income from Continuing Ops	$1.2B
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$1.2B
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$1.2B
D&A	$73M
EBIT	$1.6B
EBITDA	$1.7B
EPS	$26
EPS Diluted	$25

Cash Flow Statement

Item	Amount
Net Income	$1.2B
Depreciation & Amortization	$73M
Stock-Based Compensation	$144M
Deferred Income Tax	$0
Other Non-Cash Items	-$24M
Change in Working Capital	-$60M
OPERATING CASH FLOW	$1.3B
Capital Expenditure	-$247M
Acquisitions (Net)	-$31M
Purchases of Investments	-$1.6B
Sales/Maturities of Investments	$2.4B
Other Investing Activities	-$29M
NET CASH FROM INVESTING	$417M
Net Debt Issuance	-$400M
Common Stock Repurchased	-$1.0B
Common Dividends Paid	$0
Other Financing Activities	$157M
NET CASH FROM FINANCING	-$1.3B
FREE CASH FLOW	$1.1B
Net Change in Cash	$490M

Balance Sheet

Item	Amount
Cash & Equivalents	$1.7B
Short-Term Investments	$1.6B
Net Receivables	$279M
Inventory	$158M
Other Current Assets	$170M
TOTAL CURRENT ASSETS	$3.9B
PP&E (Net)	$1.2B
Goodwill	$32M
Intangible Assets	$80M
Long-Term Investments	$1.5B
Tax Assets	$458M
Other Non-Current Assets	$222M
TOTAL NON-CURRENT ASSETS	$3.5B
TOTAL ASSETS	$7.4B
Account Payables	$6M
Short-Term Debt	$300M
Deferred Revenue	$0
Other Current Liabilities	$432M
TOTAL CURRENT LIABILITIES	$738M
Long-Term Debt	$0
Deferred Revenue NC	$0
Deferred Tax Liabilities	$0
Other Non-Current Liabilities	$182M
TOTAL NON-CURRENT LIABILITIES	$182M
TOTAL LIABILITIES	$920M
Common Stock	$800.0K
Additional Paid-In Capital	$2.7B
Retained Earnings	$7.2B
Treasury Stock	-$3.5B
Accum. Other Comp. Income	-$3M
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$6.4B
Minority Interest	$0
TOTAL EQUITY	$6.4B
TOTAL LIABILITIES & EQUITY	$7.4B
Total Debt	$300M
Net Debt	-$1.4B